Cargando…
DDRE-14. DE-NOVO PURINE BIOSYNTHESIS IS A MAJOR DRIVER OF CHEMORESISTANCE IN GLIOBLASTOMA
Glioblastoma is a primary brain cancer with a near 100% recurrence rate. Upon recurrence, the tumor is resistant to all conventional therapies, and because of this, 5-year survival is dismal. One of the major drivers of this high recurrence rate is glioblastoma cells’ ability to adapt to complex cha...
Autor principal: | Ahmed, Atique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7994323/ http://dx.doi.org/10.1093/noajnl/vdab024.036 |
Ejemplares similares
-
DDRE-28. MECHANISTIC AND THERAPEUTIC LINKS BETWEEN PURINE BIOSYNTHESIS AND DNA DAMAGE IN GLIOBLASTOMA
por: Scott, Andrew, et al.
Publicado: (2021) -
DDRE-24. TARGETING PURINE METABOLISM TO OVERCOME GLIOBLASTOMA THERAPY RESISTANCE
por: Zhou, Weihua, et al.
Publicado: (2021) -
DDRE-11. TARGETING FATTY ACID BIOSYNTHESIS IN GLIOBLASTOMA
por: Eyme, Katharina M, et al.
Publicado: (2021) -
DDRE-09. THERAPEUTIC TARGETING OF PURINE METABOLISM IN DIPG
por: Mersich, Ian, et al.
Publicado: (2021) -
DDRE-19. PHASE 0/I TRIAL OF MYCOPHENOLATE MOFETIL COMBINED WITH RADIATION TO OVERCOME GLIOBLASTOMA TREATMENT RESISTANCE BY TARGETING DE-NOVO PURINE METABOLISM
por: Umemura, Yoshie, et al.
Publicado: (2021)